Phast Limited Secures £500k Funding to Advance Bioplastic Innovations

Phast Limited, a biotechnology company based in Sheffield, has successfully raised £500,000 in a recent funding round, achieving an estimated post-money valuation of £2.5 million. The funding, with an allotment date of April 9, 2026, and a filing date of April 29, 2026, marks a significant step for the nascent company focused on sustainable material solutions.

Founded on April 20, 2024, Phast Limited addresses the critical environmental challenge posed by conventional plastics, which fragment into persistent microplastics that accumulate in both human bodies and the environment. The company's core mission is to provide advanced bioplastics based on Polyhydroxyalkanoates (PHAs). These materials are engineered to biodegrade naturally without leaving behind harmful microplastics, offering a high-performance alternative to fossil-derived plastics. Phast's innovative bioplastics are designed for demanding applications across various sectors, including dental, medical devices, and personal care.

Currently, Phast Limited operates with a team of seven employees, according to its LinkedIn profile, though its latest accounts report two employees. The company specialises in Medical Devices, Personal Care, Sustainability, Circular Economy, Medical plastic, and Dental, reflecting its broad application potential within the bioplastics market.

This £500,000 funding round represents an early-stage investment for Phast Limited. While specific details on previous funding rounds are not available, this capital injection positions the company to further develop its biotechnological innovations. The estimated post-money valuation of £2.5 million reflects investor confidence in Phast's technology and its potential to disrupt the traditional plastics market with sustainable alternatives.

The funding landscape for UK biotechnology companies has shown signs of recovery in early 2026. In the first quarter of 2026, total equity financing for the UK biotech sector reached £552 million, an 18% increase from the previous quarter, with venture capital investment rising to £516 million. This period saw a broader distribution of capital across companies, with 25 deals completed, a substantial increase from 15 deals in Q1 2025. Early-stage activity, particularly seed rounds, also strengthened in volume terms, with ten seed deals completed in Q1 2026, up from eight in Q4 2025. The average seed deal size in Q1 2026 was approximately £4.2 million. Phast Limited's £500,000 round, while smaller than this average, aligns with the increased number of early-stage investments observed.

The sustainable materials and biosolutions sector, in which Phast operates, is also attracting growing attention. In 2025, UK biosolutions companies collectively raised £259 million in equity financing. Specifically, the chemicals and materials sub-sector secured £67 million, highlighting a rising demand for sustainable alternatives to conventional materials. Venture capital plays a dominant role in funding this sector, often complemented by government-backed initiatives like the UK Innovation and Science Seed Fund, which supports early-stage technology companies stemming from the UK's research base. The UK's biosolutions companies also attract a significant international investor base, with over 60% of investors located overseas.

Despite a challenging financing environment in 2025, which saw a decline in overall venture capital investment for UK biotech compared to 2024, deal activity showed an acceleration towards the end of the year. The UK maintained its position as Europe's leading national biotech market, accounting for 30% of all European venture financing in 2025. The investment in Phast Limited reflects the ongoing confidence in innovative UK science, particularly in areas addressing critical environmental and health needs through advanced biotechnology.